SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-99.1
Date Filed: 2025-11-13
Accession Number: 0001213900-25-109585
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025109585/ea026529201ex99-1_synergy.htm

Chunk 1 of 2
Word Count: 1024
Character Count: 7296

Document Content:

date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy’s filings could cause its actual results to differ materially from those contained in any forward-looking statement. Investor Relations Gateway Group Cody Slach, Greg Robles SNYR@gateway-grp.com Synergy CHC Corp. Condensed Consolidated Balance Sheets September 30, 2025 December 31, 2024 (unaudited) Assets Current Assets Cash and cash equivalents $ 1,006,489 $ 687,920 Restricted cash 100,000 100,000 Accounts receivable, net 6,812,649 5,321,037 Other receivables 2,182,755 1,999,637

Loan receivable (related party) 4,407,449 4,375,059

Prepaid expenses (including related party amount of $1,050,212 and $312,966, respectively) 3,852,311 1,859,563

Inventory, net 2,145,966 1,716,552

Total Current Assets 20,507,619 16,059,768

Intangible assets, net 183,333 283,333

Total Assets $	20,690,952 $	16,343,101

Liabilities and Stockholders’ Deficit

Current Liabilities:

Accounts payable and accrued liabilities (including payable to shareholder of $88,770 and $88,644, respectively) $	3,573,505 $	5,191,868

Income taxes payable 254,763 242,977

Contract liabilities 1,854 24,252

Short term loans payable, net of debt discount - 7,725,272

Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder - 4,000,000

Total Current Liabilities 3,830,122 17,184,369

Long-term Liabilities:

Notes payable, net of debt discount, shareholder - 8,333,053

Notes payable, net of debt discount 25,113,177 7,457,022

Total long-term liabilities 25,113,177 15,790,075

Total Liabilities 28,943,299 32,974,444

Commitments and contingencies

Stockholders’ Deficit:

Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,431,926 and 8,721,818, shares issued, respectively; 11,251,853 and 8,541,745 outstanding, respectively 114 87

Additional paid in capital 33,535,939 27,643,660

Accumulated other comprehensive loss (35,915	) (47,777	)

Accumulated deficit (41,624,985	) (44,099,813	)

Less: Treasury stock (180,073 shares) at cost (127,500	) (127,500	)

Total stockholders’ deficit (8,252,347	) (16,631,343	)

Total Liabilities and Stockholders’ Deficit $	20,690,952 $	16,343,101

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of
Income and Comprehensive Income

For the three months ended For the nine months ended

September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024

Revenue

Product Sales $	8,010,112 $	7,126,333 $	21,415,642 $	24,563,039

License Revenue - - 2,900,000 -

Total Revenue 8,010,112 7,126,333 24,315,642 24,563,039

Cost of sales 2,329,296 2,335,901 6,232,201 7,421,930

Gross profit 5,680,816 4,790,432 18,083,441 17,141,106

Operating expenses

Selling and marketing 2,729,767 2,509,440 8,668,249 9,149,303

General and administrative 1,637,706 1,196,784 4,463,745 3,449,007

Depreciation and amortization 33,333 33,333 100,000 100,000

Total operating expenses 4,400,806 3,739,557 13,231,994 12,698,310

Income from operations 1,280,010 1,050,875 4,851,447 4,442,796

Other (income) expenses

Other income (252,405	) (252,405	)

Interest income

Interest expense, net 1,164,017 704,707 4,352,840 2,559,454

Gain on settlement of notes payable - (2,154,522	) -

Remeasurement loss on translation of foreign subsidiary 1,773 7,279 10,762 2,166

Total other (income) expenses 1,165,790 459,581 2,209,080 2,309,215

Net income before income taxes 114,220 591,294 2,642,367 2,133,581

Income tax benefit (expense) 11,107 192,299 (167,540	) (114,272	)

Net income after tax $	125,327 $	783,593 $	2,474,827 $	2,019,309

Net income per share – basic $	0.01 $	0.11 $	0.27 $	0.27

Net income per share – diluted $	0.01 $	0.11 $	0.27 $	0.27

Weighted average common shares outstanding

Basic 10,110,114 7,373,745 9,204,136 7,373,745

Diluted 10,111,134 7,373,745 9,204,136 7,373,745

Comprehensive income:

Net income 125,327 783,593 2,474,827 2,019,309

Foreign currency translation adjustment (26,077	) (79,025	) 11,862 108,348

Comprehensive income $	99,250 $	704,568 $	2,486,689 $	2,127,657

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of
Cash Flows

For the nine months ended For the nine months ended

September 30, 2025 September 30, 2024

Cash Flows from Operating Activities

Net income $	2,474,827 $	2,019,309

Adjustments to reconcile net income to net cash used in operating activities:

Amortization of debt discount and debt issuance cost 1,128,795 47,519

Depreciation and amortization 100,000 100,000

Stock based compensation 19,941 9,224

Stock issued for modification of notes payable 847,062 -

Stock issued for services 127,200 -

Foreign currency transaction loss 5,655 23,777

Remeasurement loss on translation of foreign subsidiary 10,763 2,166

Non cash implied interest - 4,799

Gain on settlement of debt (2,154,522	) -

Changes in operating assets and liabilities:

Accounts receivable (1,491,612	) (1,965,936	)

Other receivables (183,118	) -

Loan receivable, related party (32,390	) 21,269

Inventory (429,414	) 1,815,725

Prepaid expenses (1,255,502	) (205,975	)

Prepaid expense, related party (737,246	) (396,683	)

Income taxes payable 11,786 68,607

Contract liabilities (22,398	) (12,102	)

Accounts payable and accrued liabilities (2,009,905	) (3,011,384	)

Accounts payable, shareholder 380,929 102,206

Net cash used in operating activities (3,209,149	) (1,377,479	)

Cash Flows from Investing Activities - -

Cash Flows from Financing Activities

Proceeds from issuing common stock 3,880,462 -

Advances from related party 135,000 3,395,587

Repayment of advances from related party (135,000	) (157,425	)

Proceeds from notes payable 18,996,250 600,000

Payment of loan financing fees (2,010,953	) -

Repayment of notes payable, shareholder (10,000,000	) (84,500	)

Repayment of notes payable (7, 349,903	) (2,857,690	)

Net cash provided by financing activities 3,515,856 895,972

Effect of exchange rate on cash, cash equivalents and restricted cash 11,862 108,348

Net increase (decrease) in cash, cash equivalents and restricted cash 318,569 (373,159	)

Cash and restricted cash, beginning of year 787,920 732,534

Cash and restricted cash, end of period $	1,106,489 $	359,375

Supplemental Disclosure of Cash Flow Information:

Cash paid during the period for:

Interest $	1,824,446 $	2,432,653

Income taxes $	- $	45,664

Supplemental Disclosure of Noncash Investing and Financing Activities:

Accounts payable converted to loan payable upon settlement $	- $	3,770,824

Reduction of short term related party note payable by reduction of prepaid balance $	- $	328,003

Issuance of common stock for loan financing $	117,648 $	-

Issuance of pre-funded warrants for settlement of shareholder notes payable $	899,993 $	-

Exercise of pre-funded warrants $	4 $	-

Loan fees payable to lender $	375,000 $	-